This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. Specific indications include major depressive disorder, treatment-resistant depression, dysthymia, bipolar depression, and postpartum depression, among others. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in August 2024. It is likely to become outdated with time.
Under development
Phase 3 Cycloserine/lurasidone (Cyclurad; NRX-101) – ionotropic glutamate NMDA receptor glycine site partial agonist and atypical antipsychotic (non-selective monoamine receptor modulator) combination Deupsilocin (HLP003; HLP-003; CYB003; CYB-003; deuterated psilocybin analogue; deuterated psilocin) – serotonin 5-HT2A receptor agonist and psychedelic hallucinogen Esmethadone (dextromethadone; REL-1017) – ionotropic glutamate NMDA receptor antagonist and other actions Ketamine (HTX-100; NRX-100) – ionotropic glutamate NMDA receptor antagonist Lysergic acid diethylamide (LSD; MM-120) – non-selective serotonin receptor agonist and psychedelic hallucinogen Navacaprant (BTRX-140; BTRX-335140; CYM-53093; NMRA-140; NMRA-335140) – κ-opioid receptor antagonist Osavampator (TAK-653; NBI-1065845; NBI-845) – ionotropic glutamate AMPA receptor positive allosteric modulator Pimavanserin (ACP-103; BVF-048; Nuplazid) – serotonin 5-HT2A receptor antagonist or inverse agonist Psilocybin (COMP-360) – non-selective serotonin receptor agonist and psychedelic hallucinogen Psilocybin (Usona Institute) – non-selective serotonin receptor agonist and psychedelic hallucinogen Seltorexant (JNJ-42847922; JNJ-7922; MIN-202) – orexin OX2 receptor antagonist SEP-4199 (non-racemic amisulpride; aramisulpride/esamisulpride [85:15 ratio]) – atypical antipsychotic (dopamine D2 and D3 receptor antagonist and serotonin 5-HT2B and 5-HT7 receptor antagonist) SNG-12 (Synapsinae) – glycine transporter 1 (GlyT1) inhibitor Solriamfetol (Sunosi; JZP-110; SKLN05; ARL-N05; YKP-10A; R-228060; ADX-N05) – norepinephrine and dopamine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist Ulotaront (SEP-363856; SEP-856) – serotonin 5-HT1A receptor agonist and trace amine-associated receptor 1 (TAAR1) agonist
Phase 2/3 PRAX-114 – extrasynaptic GABAA receptor-preferring positive allosteric modulator and neurosteroid
… excerpt ends here. Continue reading the full article.
